Spain: Researchers from the Complutense University of Madrid, Spain, the Military Medical College, Belgrade, Serbia, and the University of Michigan in Ann Arbor, Michigan, USA, are working on a solution to peri-implant mucositis (PIM).

The study, titled "Resolution of peri-implant mucositis after standard therapy: a prospective split-mouth study", delves into the effectiveness of standard anti-infective mechanical therapy (AIMT) for PIM and the diagnostic potential of bone markers.

PIM: a precursor to peri-implantitis

Peri-implantitis is a growing public health problem, affecting patient cognition, treatment costs, and overall health. The prevalence is estimated to be as high as 30%, and the lack of predictive treatment options and the high rate of recurrence in the first two years after treatment are significant challenges. The study focuses on peri-implant mucositis (a precursor to peri-implantitis) and aims to understand its progression and effective treatment strategies.

Despite the increasing prevalence of peri-implantitis, standard diagnosis in implantology relies on clinical parameters that are often influenced by factors such as dental implant technique and individual bone remodeling characteristics. Biomarkers recommended by leading dental organizations are proposed as valuable additions to diagnostic protocols.

Unravel the complexities of PIM

Peri-implant mucositis, defined as an inflammatory disease of the soft tissues around implants, poses a diagnostic challenge due to its reversible course and unclear mode of transformation to peri-implantitis. The study leveraged machine learning algorithms to identify a cohort of PIM patients who exhibited excessive osteoclast-promoting markers, revealing the complexity of the condition.

The research team investigated the diagnostic capabilities of biomarkers such as RANKL, OPG, and IGFBP2 as surrogate endpoints and predictors. Previous studies have highlighted the specificity of RANKL in differentiating peri-implant conditions, thereby improving the accuracy of clinical diagnosis. IGFBP-2 becomes a promising predictor of bone resorption and a potential surrogate endpoint for treatment evaluation.

While AIMT has been shown to be effective in reducing clinical and biological markers of PIM, only 30% of cases achieve complete clinical resolution. The study prompted a re-evaluation of standard treatment options and highlighted the need for a more predictive diagnostic approach in implant dentistry. Understanding the complexity of PIM progression and treatment response is critical to advancing implant care strategies.